Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Cancer
NCT00165217Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2001
- Primary completion
- Dec 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and thalidomide in colorectal adenocarcinoma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Anti-tumor activity at 9 weeks. Started Nov 2001; status: completed.
02
Drugs
capecitabinethalidomide
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT00165217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165217.